Prometheus, an AI “clinical engineering” startup, raised $12 billion to build “artificial general engineers” and expand use cases across biopharma workflows, including trial operations. The funding appears aimed at automating parts of clinical development, with the company citing applications such as improving trial recruitment efficiency. The broader funding activity around AI infrastructure and execution tools continues to show up in biopharma partnerships as well: the same coverage referenced Abridge’s partnerships involving Eli Lilly and Nvidia to optimize clinical trial recruitment. For the industry, the Prometheus raise underlines how capital is concentrating on software layers that can compress development timelines through operational automation rather than only drug discovery models.